Compare · DFTX vs OBIO
DFTX vs OBIO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 18.7x OBIO ($322.2M).
- DFTX has been more active in the news (15 items in the past 4 weeks vs 8 for OBIO).
- OBIO has more recent analyst coverage (9 ratings vs 7 for DFTX).
- Company
- Definium Therapeutics Inc.
- Orchestra BioMed Holdings Inc.
- Price
- -
- -
- Market cap
- $6.02B
- $322.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 8
- Recent ratings
- 7
- 9
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest OBIO
- Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Director Mack John Prosper covered exercise/tax liability with 4,885 shares, decreasing direct ownership by 7% to 66,544 units (SEC Form 4) (tax liability)
- Director Fain Eric S covered exercise/tax liability with 5,145 shares (SEC Form 4) (withholding obligation)
- Director Pacitti David covered exercise/tax liability with 3,761 shares, decreasing direct ownership by 6% to 54,750 units (SEC Form 4) to satisfy withholding tax
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Orchestra BioMed Holdings Inc.
- Officer Sherman Darren sold $61,350 worth of shares (15,000 units at $4.09) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,154,327 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Officer Sherman Darren sold $64,050 worth of shares (15,000 units at $4.27) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,169,327 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.